

## Special Issue

# Immunity at the Gate of Entrance; Vaccines against Respiratory Viruses such as Influenza and RSV

### Message from the Guest Editor

Most vaccines induce systemic immunity through intramuscular administration. This route of vaccination disregards a very potent part of the immune system—local adaptive immunity. There is a limited amount of locally administered respiratory vaccines available. Challenges include adjuvation, formulation, and induction of long-lasting immunity. For both RSV and influenza immunity, longevity is a holy grail. Therefore, research that provides insight into local immune parameters that correlate with protection against respiratory viruses or that are shown to be long-lasting is welcomed. Immune induction may be through vaccination, using adjuvants and formulation techniques to steer the immune response or by immune transfer techniques, etc. when this leads to a better understanding of potent vaccine targets. Combining insights and strategies developed for different respiratory viruses into one Special Issue encourages cross-pollination of the different research fields and would advance the development of locally administered respiratory vaccines on the whole.

### Guest Editor

Dr. Jorgen De Jonge

Department for Immune Mechanisms, Centre for Infectious Disease Control, National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands

### Deadline for manuscript submissions

closed (31 October 2020)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/40966](https://mdpi.com/si/40966)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).